Optimizing patient Engagement in Trials

Before the pandemic hit, the value for all parties in involving patients as key stakeholders in trial recruitment, design and execution was already becoming clear for pharma businesses, leading to more successful trials for them and better outcomes for patients.   Now, this dynamic has been shown to be even more apparent and important, says Madeline Geday, Director, Global Patient Engagement and Innovation at MSD. “Patients, especially with technology today, understand more than they ever have, and we should as an industry try to give our patients more.   Strong relationships with patient and advocacy groups can improve trial success rates and generate important insights for product development, she adds.   “Patient engagement is instrumental to having better patient experiences that lead to increased participation. Patients are also more likely to adhere to the protocol in trial design. If they ' re more engaged, there ' s going to be a reduction in dropout rates, which can, in turn, speed up the delivery of medicines to market, ” says Geday.   Especially in light of COVID, clinical trial staff have also been listening to patients and patient advocacy groups when planning for diversity and incorporating a diverse patient population into the trials, she notes.   Including the patient from start to finish Participation from trial design to conclusion is one key to achieving such outcomes, Cynthia Chmielewski, a patient advocate. “Patients should participat...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news